Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Fujirebio Diagnostics Inc. is currently prosecuting 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This singular active matter represents the company's current focus in its intellectual property strategy. The concentration of effort in the diagnostics and biotechnology sector suggests a specialized technological priority for the company's current filings.
The prosecution environment for this portfolio is highly centralized, with 1 distinct examiner and 1 distinct art unit involved. This indicates that the company's active patent claims are being reviewed by a single official within a specialized division of the USPTO. This narrow focus means that the company's immediate success is tied to the technical standards and precedents of that 1 distinct art unit.
SULLIVAN, DENNIS JOHN is identified as the busiest examiner for the portfolio, currently overseeing 1 pending office action. As the sole examiner for the company's active filings, their individual perspective on the claims will determine the immediate outcome of the prosecution. Practitioners should analyze the specific examination tendencies of this official to move the 1 pending office action toward allowance in the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SULLIVAN, DENNIS JOHN | 1 | 57.6% | +48.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18629164 | Use of HE4 and other biochemical markers for assessment of endometrial and uterine cancers | SULLIVAN, DENNIS JOHN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18629164 | Use of HE4 and other biochemical markers for assessment of endometrial and uterine cancers | SULLIVAN, DENNIS JOHN | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18629164 | Use of HE4 and other biochemical markers for assessment of endometrial and uterine cancers | SULLIVAN, DENNIS JOHN | 1642 | §101§103§112 | Final Rejection | — | Pending | Apr 08, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFujirebio Diagnostics Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dennis John Sullivan has the most, with 1 of Fujirebio Diagnostics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
